171 related articles for article (PubMed ID: 36961524)
1. Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma.
Legros L; Pascale A; Guettier C; Eftekhari P; Merabet YB; Stang M; Bossevot R; Goldschmidt E; Ulusakarya A; Morisset S; Lewin M; Samuel D; Rosmorduc O
Cancer Chemother Pharmacol; 2023 Apr; 91(4):337-344. PubMed ID: 36961524
[TBL] [Abstract][Full Text] [Related]
2. Sustained erythrocytosis due to the use of Lenvatinib.
Kaur J; Tuler S; Dasanu CA
J Oncol Pharm Pract; 2022 Mar; 28(2):475-478. PubMed ID: 34665694
[TBL] [Abstract][Full Text] [Related]
3. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma.
Koizumi Y; Hirooka M; Hiraoka A; Ochi H; Tanaka T; Yukimoto A; Imai Y; Watanabe T; Yoshida O; Miyake T; Matsuura B; Michitaka K; Joko K; Abe M; Hiasa Y
Endocr J; 2019 Sep; 66(9):787-792. PubMed ID: 31142692
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of erythrocytosis in patients with hepatocellular carcinoma.
Hwang SJ; Lee SD; Wu JC; Chang CF; Lu CL; Tsay SH; Lo KJ
Zhonghua Yi Xue Za Zhi (Taipei); 1994 May; 53(5):262-9. PubMed ID: 7518732
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
8. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
9. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
10. Serum erythropoietin measurements by a one-step sandwich enzyme linked immunosorbent assay in patients with hepatocellular carcinoma and liver cirrhosis.
Sawabe Y; Iida S; Tabata Y; Yonemitsu H
Jpn J Clin Oncol; 1993 Oct; 23(5):273-7. PubMed ID: 7693989
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytosis caused by an erythropoietin-producing hepatocellular carcinoma.
Matsuyama M; Yamazaki O; Horii K; Higaki I; Kawai S; Mikami S; Higashino M; Oka H; Nakai T; Inoue T
J Surg Oncol; 2000 Nov; 75(3):197-202. PubMed ID: 11088052
[TBL] [Abstract][Full Text] [Related]
12. [A Case of Hepatocellular Carcinoma with Erythrocytosis].
Mitsuhashi N; Sai G; Shimizu Y; Sakai N; Suzuki D; Kuboki S; Furukawa K; Ohtsuka M
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1771-1773. PubMed ID: 36732994
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study.
Patwala K; Prince DS; Celermajer Y; Alam W; Paul E; Strasser SI; McCaughan GW; Gow P; Sood S; Murphy E; Roberts S; Freeman E; Stratton E; Davison SA; Levy MT; Clark-Dickson M; Nguyen V; Bell S; Nicoll A; Bloom A; Lee AU; Ryan M; Howell J; Valaydon Z; Mack A; Liu K; Dev A
Hepatol Int; 2022 Oct; 16(5):1170-1178. PubMed ID: 36006547
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma.
Kim Y; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Goh MJ; Kang W; Kim SU
Eur J Gastroenterol Hepatol; 2023 Feb; 35(2):191-197. PubMed ID: 36574310
[TBL] [Abstract][Full Text] [Related]
15. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
[TBL] [Abstract][Full Text] [Related]
16. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
[TBL] [Abstract][Full Text] [Related]
17. A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Hatanaka T; Kakizaki S; Nagashima T; Ueno T; Namikawa M; Tojima H; Takizawa D; Naganuma A; Arai H; Sato K; Harimoto N; Shirabe K; Uraoka T
Acta Gastroenterol Belg; 2021; 84(1):65-72. PubMed ID: 33639695
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center.
Cosma LS; Weigand K; Müller-Schilling M; Kandulski A
J Gastrointestin Liver Dis; 2021 Jun; 30(2):247-253. PubMed ID: 33951122
[TBL] [Abstract][Full Text] [Related]
19. Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2089-2093. PubMed ID: 32234901
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report.
Kohya R; Sugiura R; Yamamoto Y; Naruse H; Hatanaka K; Kinoshita K; Abiko S; Miyamoto S; Suzuki K; Kushibiki H; Munakata S; Shimoyama N
Intern Med; 2023 Apr; 62(7):995-998. PubMed ID: 36047124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
